Literature DB >> 23572059

Impact of inflammation on adverse cardiovascular events in patients with acute coronary syndromes.

Michael Fiechter1, Jelena R Ghadri, Milosz Jaguszewski, Asim Siddique, Severin Vogt, Raphael B Haller, Robin Halioua, Armin Handzic, Philipp A Kaufmann, Roberto Corti, Thomas F Lüscher, Christian Templin.   

Abstract

AIMS: Inflammation is a key factor in the long-term outcome of acute coronary syndromes (ACS). The aim of the present study was to evaluate inflammatory markers in patients with ACS as predictors for major adverse cardiovascular events (MACE) and hard events.
METHODS: This study included 1548 patients with ACS. C-reactive protein (CRP), white blood count (WBC), and their subtypes were analyzed during hospitalization. Receiver operator characteristic (ROC) and Kaplan-Meier survival curves were used to assess the predictive value and hard events (nonfatal myocardial infarction and cardiac death) and MACE (hard events, hospitalization for cardiac causes, late revascularization and stroke) were obtained during 30 days.
RESULTS: ROC analysis of CRP and WBC to predict adverse events revealed cut-offs of 47.5 ng/l and 16.6 × 10/μl for MACE and 93.5 ng/l and 16.6 × 10/μl for hard events. The cumulative adverse event rates were significantly higher in patients with increased CRP (≥47.5 ng/l; 17 versus 4%, P < 0.001) and WBC (≥16.6 × 10/μl; 21 versus 5%, P < 0.001) for MACE and with elevated CRP (≥93.5 ng/l; 16 versus 2%, P < 0.001) and WBC (≥16.6 × 10/μl; 18 versus 2%, P < 0.001) for hard events, demonstrating highest event rates with elevation of both inflammatory markers: (28 versus 5%, P < 0.001) for MACE and (26 versus 2%, P < 0.001) for hard events. Analysis of CRP and WBC further revealed a substantial negative correlation with left ventricular function (P < 0.001). Moreover, markers of myocardial damage were significantly elevated in patients with abnormal CRP or WBC (P < 0.001).
CONCLUSION: Inflammatory markers such as CRP and WBC alone and, particularly, in combination are strong and independent predictors of outcome in patients with ACS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572059     DOI: 10.2459/JCM.0b013e3283609350

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  10 in total

1.  Acute coronary syndromes in octogenarians referred for invasive evaluation: treatment profile and outcomes.

Authors:  Milosz Jaguszewski; Jelena-R Ghadri; Johanna Diekmann; Roxana D Bataiosu; Jens P Hellermann; Annahita Sarcon; Asim Siddique; Lukas Baumann; Barbara E Stähli; Thomas F Lüscher; Willibald Maier; Christian Templin
Journal:  Clin Res Cardiol       Date:  2014-08-21       Impact factor: 5.460

2.  Temporal Changes in Pollen Concentration Predict Short-Term Clinical Outcomes in Acute Coronary Syndromes.

Authors:  Omar Al-Mukhtar; Sara Vogrin; Edwin R Lampugnani; Samer Noaman; Diem T Dinh; Angela L Brennan; Christopher Reid; Jeffrey Lefkovits; Nicholas Cox; Dion Stub; William Chan
Journal:  J Am Heart Assoc       Date:  2022-03-15       Impact factor: 6.106

3.  Novel predictors of infarct-related artery patency for ST-segment elevation myocardial infarction: Platelet-to-lymphocyte ratio, uric acid, and neutrophil-to-lymphocyte ratio.

Authors:  Halit Acet; Faruk Ertaş; Mehmet Ata Akıl; Ferhat Özyurtlu; Abdülkadir Yıldız; Nihat Polat; Mehmet Zihni Bilik; Mesut Aydın; Mustafa Oylumlu; Hasan Kaya; Murat Yüksel; Abdurrahman Akyüz; Hilal Ayçiçek; Sait Alan; Nizamettin Toprak
Journal:  Anatol J Cardiol       Date:  2014-07-11       Impact factor: 1.596

4.  Factors associated with acute myocardial infarction in older patients after hospitalization with community-acquired pneumonia: a cross-sectional study.

Authors:  Yu Kang; Xiang-Yang Fang; Dong Wang; Xiao-Juan Wang
Journal:  BMC Geriatr       Date:  2021-02-09       Impact factor: 3.921

5.  Utility of Elevated Pentraxin-3 Level as Inflammatory Marker for Predicting Adverse Outcomes in Patients With Acute Coronary Syndrome: A Meta-Analysis.

Authors:  Yu Fan; Rong He; Changfeng Man; Dandan Gong
Journal:  Front Cardiovasc Med       Date:  2022-01-20

6.  The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Chen Li; Hualin Fan; Yuanhui Liu; Lihuan Zeng; Pengyuan Chen; Chongyang Duan; Huasheng Liang; Pengcheng He
Journal:  Ann Transl Med       Date:  2021-11

7.  MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction.

Authors:  Shengjue Xiao; Tongneng Xue; Qinyuan Pan; Yue Hu; Qi Wu; Qiaozhi Liu; Xiaotong Wang; Ailin Liu; Jie Liu; Hong Zhu; Yufei Zhou; Defeng Pan
Journal:  Cardiovasc Ther       Date:  2021-10-25       Impact factor: 3.023

8.  Systemic Immune-Inflammation Index Predicts Major Cardiovascular Adverse Events in Patients with ST-Segment Elevated Myocardial Infarction.

Authors:  Faysal Saylik; Tayyar Akbulut
Journal:  Arq Bras Cardiol       Date:  2022-07       Impact factor: 2.667

9.  Two parameters reflect lipid-driven inflammatory state in acute coronary syndrome: atherogenic index of plasma, neutrophil-lymphocyte ratio.

Authors:  Youqin Zhan; Tan Xu; Xuerui Tan
Journal:  BMC Cardiovasc Disord       Date:  2016-05-17       Impact factor: 2.298

Review 10.  ST-elevation myocardial infarction following systemic inflammatory response syndrome.

Authors:  Ying Tan; Yan Tu; Di Tian; Chen Li; Jian-Kai Zhong; Zhi-Gang Guo
Journal:  Cardiovasc J Afr       Date:  2015-05-23       Impact factor: 1.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.